

PC25378A
Response to Restriction Requirement for USSN 10/669,812



17W
Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:
Mail Stop: Amendment, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450
on this 16th day of December 2005.

s/ 
Julie Agostino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Oscar Barba, et al.

Serial No.: 10/669,812

Confirmation No.: 7011

Filed: September 23, 2003

For: PYRAZOLE DERIVATIVES

Group Art Unit: 1626

Examiner: KAMAL A. SAEED

RESPONSE TO RESTRICTION REQUIREMENT


Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sirs:

This is a response to the Office Action dated December 1, 2005, for Applicant's Docket number PC25378A. The Examiner required Applicant to elect one of the following inventions for examination in this application: (I) Claims 1-9 and 16; (II) Claims 10-14; or (III) Claim 15.

Applicant hereby elects Group (I), Claims 1-9 and 16. This election is without traverse.

Further, the Examiner required election of a single compound. Applicant submits that the compound of Example 1 (reproduced below) is elected as a representative species:



CONCLUSION

If any fee not submitted herewith is required for the filing of this response, including any fee for an extension of time for which Applicant hereby petitions, please charge all such necessary fees to Applicant's Deposit Account No. 500329.

Respectfully submitted,

Date: Dec. 16, 2005

Keith D. Hutchinson
Keith D. Hutchinson
Attorney For Applicants
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4608
Fax: (858) 678-8233